Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Whenever they issue PRs confirming that NRXP is a collaboration partner, they should include the revenue sharing breakdown so investors understand how this is beneficial to Relief.
It’s concerning that NRXP is not mentioning Relief in its PRs as a collaboration partner.
Holding. I sold some earlier this year. I've been in it for this long. What about you?
Yep.
Agreed but that was all the talk around the holidays about how they would RS to uplist.
No mention of up list.
I will. Been in since 2014. Seems like a great opportunity but management just can’t execute. A shame.
Still boggles my mind that this type of manipulation is legal.
I agree but no way to tell what the FDA is thinking.
My only fear is that with cases and hospitalizations dropping, which is a good thing, the FDA takes the position, EUA is no longer needed and they need to go the full approval route. Thoughts from people?
If that’s the case then why has NeuroRx mentioned its collaboration with Relief in all of its PRs for the IV trial and no mention of SUNY?
Got it. None for severe COVID. The real value is that this isn’t just a COVID play.
Smoke inhalation, COPD, cystic fibrosis
This is not a COVID only drug.
That is the responsibility of Relief.
Relief needs to PR this as well and let everyone know that they are partners on this.
BRPA just rocketed up $7.
Is this an effort to create FOMO?
If the news is bad, why not drop the results after hours on Friday? Why do it at the beginning of the week?
Javitt appears to be doing more interviews since the study was unblinded. Part of me wants to believe he wouldn’t be doing these if he knew the data wasn’t good.
Ok. Thanks. I was hoping the company would confirm.
J-Belfort, as a person with a significant investment in Relief, do you know if Relief is a PFIC? I have emailed the company and investor relations numerous times about this but have not received any responses. Thanks.
Does anyone know if Relief is a PFIC? I think it maybe, which has tax consequences but cannot find any info on the website and I emailed Investor Relations numerous times and have not received any responses.
Wouldn’t have been better to design the trial such that only ZYESAMI was given to patients in one arm and the SOC Remdesivir given to patients in the other arm? This way, if they received the results that they did showing reduced hospitalization in the ZYESAMI arm, that would be a good argument for making ZYESAMI the new SOC.
Why report preliminary data that may not appear positive? Maybe there is other positive news that will be discussed on the call. We shall see.
I guess we are not getting dial in information. Why make an announcement and not follow through?
BRPA is up +10% pre market.
It is a little discouraging. They should have the results. Based on data from the previous 100 patients, i think it is unlikely, the phase 2b/3 results would differ significantly. There must he other reasons for delaying the readout.
They can’t as this is insider info.
In ths market' anything is possible. Is GME a $28B dollar company? Crazy.
Ok. So we need money and keep raising money and now we are loaning money to another company, which can lead to more dilution for us? Either they know the results are positive and money will be coming in or they are incompetent.
For number of patients, the update states 196 [actual]. Does this mean there have been 196 patients enrolled as of the update? And is this complete enrollment?
BRPA is going ballistic.
And none of this moves the needle. Very frustrating.
The typical hold up with EUA is because they want to make sure the drug is safe with no severe AEs. Here, there is a ton of historical data showing showing Aviptadil is safe. Very frustrating with the governmental bureaucracy. Really no risk to patients other than saving their life.
I’m so done with the OTC. It’s the same BS with each company. At this point, i just want to break even. I find it hard to believe that if the results are that good, why we cannot get any traction. And what happened to the peer review?
How are the Swiss reacting to this news?